Foundations and history
Lessons 01–02L · 01
Psychedelics and Psychedelic-Assisted Therapy: Definitions, Effects and How to Weigh ClaimsStudents define classic psychedelics, entactogens, dissociatives and atypical agents, describe their subjective effects and how they are measured, read Canadian survey data on use, and apply a checklist for weighing claims about psychedelic-assisted therapy.
L · 02
Histories: Ceremony, Canadian Psychiatry, Prohibition and RevivalThe lesson traces peyote, mushroom, ayahuasca and iboga traditions, mid-century psychiatry in Saskatchewan and Montreal, coercive research and prohibition, and the research revival, with attention to Indigenous sources and consent.
How psychedelics work
Lessons 03–05L · 03
Pharmacology of Psychedelics: Receptors, Pharmacokinetics, Dose and InteractionsStudents apply receptor pharmacology to psilocybin, LSD, DMT, MDMA, ketamine and ibogaine, relate pharmacokinetics to the length of a session, and screen medications for interactions and cardiac risk.
L · 04
How Psychedelics Change the Brain: Networks, Plasticity and LearningThe lesson examines brain network findings, neuroplasticity in cells, animals and people, fear extinction and memory reconsolidation, and the gaps between mechanism studies and clinical benefit.
L · 05
The Psychedelic Experience: Mystical States, Set and Setting, Expectancy and BlindingStudents examine mystical-type and challenging experiences, set and setting, expectancy and functional unblinding, and what experience measures can and cannot show about why people improve.
Clinical practice
Lessons 06–07L · 06
Safety, Screening and Risk ManagementThe lesson covers cardiovascular, psychiatric and interaction risks, screening and exclusion criteria, monitoring during sessions, and the management and reporting of adverse events.
L · 07
The Therapeutic Process: Preparation, Dosing Sessions and IntegrationStudents follow the therapeutic process from preparation and consent, including consent to touch, through the dosing session to integration, with attention to therapy models, clinician time and the legal limits of practice in Canada.
Clinical evidence
Lessons 08–10L · 08
Psilocybin, Ketamine and Depression, Anxiety and End-of-Life DistressThe lesson reviews trials of psilocybin for cancer-related distress and depression, company-reported phase 3 results, ketamine and esketamine, and how to read response, remission and numbers needed to treat.
L · 09
MDMA-Assisted Therapy for PTSD: Evidence, Regulation and Research IntegrityStudents examine the MDMA-assisted therapy protocol, the phase 3 trials, the 2024 FDA decision, and research integrity and participant protection after misconduct at a Canadian trial site.
L · 10
Psychedelics and Addiction: Alcohol, Tobacco, Opioids and Community ModelsThe lesson reviews psychedelic trials in alcohol, tobacco and opioid use disorders, the risks of ibogaine, ayahuasca research and community models of care, set against benchmarks from standard treatment.
Access, regulation and ethics
Lessons 11–12L · 11
Access, Regulation and Practice in Canada and the WorldStudents trace the path from trial to market, Canada's access routes under the 2026 regulations and court decisions, access models in other countries, and practice and harm reduction outside clinics.
L · 12
Ethics, Equity, Training and the Future of Psychedelic PracticeThe lesson addresses ethics in altered states, training and accountability for practitioners, Indigenous knowledge and benefit sharing, equity of access, and commercialization and the future of practice.